Moleculin Biotech Inc. (MBRX), a clinical-stage pharmaceutical company, on Thursday presented preclinical data for Annamycin in treating pancreatic cancer, at the 2026 annual meeting of the American Association for Cancer Research (AACR).
Annamycin (L-ANN), the company's lead drug candidate, is a novel, non-cardiotoxic anthracycline that showed significant tumor growth inhibition in pancreatic ductal carcinoma (PDAC) models.
Preclinical testing yielded meaningful survival benefits in metastatic models, with a median survival of over 60% compared to control treatments. This indicated enhanced tumor penetration, with higher accumulation of the drug observed in pancreatic tumors. Annamycin was effective both as a monotherapy, and in combination with immune checkpoint and KRAS inhibitors.
Moleculin is currently evaluating Annamycin in combination with cytarabine (AnnAraC) in the Phase 2/3 MIRACLE trial for the treatment of relapsed/refractory acute myeloid leukemia (AML).
MBRX closed Thursday at $2.54, up 1.60%. In the overnight market, shares are trading at $2.59, up 1.97%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.